Free Trial

Supernus Pharmaceuticals (SUPN) Competitors

Supernus Pharmaceuticals logo
$33.07 -0.13 (-0.39%)
As of 12:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SUPN vs. JAZZ, PRGO, PCRX, OMER, NKTR, ASMB, CPIX, LLY, JNJ, and ABBV

Should you be buying Supernus Pharmaceuticals stock or one of its competitors? The main competitors of Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and AbbVie (ABBV). These companies are all part of the "pharmaceuticals" industry.

Supernus Pharmaceuticals vs.

Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.

Jazz Pharmaceuticals received 660 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. Likewise, 80.83% of users gave Jazz Pharmaceuticals an outperform vote while only 73.18% of users gave Supernus Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Supernus PharmaceuticalsOutperform Votes
483
73.18%
Underperform Votes
177
26.82%
Jazz PharmaceuticalsOutperform Votes
1143
80.83%
Underperform Votes
271
19.17%

Supernus Pharmaceuticals presently has a consensus price target of $36.00, suggesting a potential upside of 8.86%. Jazz Pharmaceuticals has a consensus price target of $182.79, suggesting a potential upside of 64.58%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Supernus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Supernus Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.33
Jazz Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

Jazz Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Supernus Pharmaceuticals$668.00M2.77$1.32M$1.1129.79
Jazz Pharmaceuticals$4.06B1.68$414.83M$7.5014.81

Jazz Pharmaceuticals has a net margin of 11.60% compared to Supernus Pharmaceuticals' net margin of 9.16%. Jazz Pharmaceuticals' return on equity of 29.30% beat Supernus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Supernus Pharmaceuticals9.16% 7.79% 5.67%
Jazz Pharmaceuticals 11.60%29.30%9.72%

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Supernus Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.

In the previous week, Jazz Pharmaceuticals had 15 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 22 mentions for Jazz Pharmaceuticals and 7 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.50 beat Jazz Pharmaceuticals' score of 1.29 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Supernus Pharmaceuticals
7 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jazz Pharmaceuticals
18 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 13 of the 18 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SUPN vs. The Competition

MetricSupernus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.85B$6.58B$5.41B$8.53B
Dividend YieldN/A2.66%5.22%4.11%
P/E Ratio30.949.2126.7719.96
Price / Sales2.77257.57395.44121.37
Price / Cash21.8365.8538.2534.62
Price / Book1.966.576.874.60
Net Income$1.32M$144.25M$3.23B$248.27M
7 Day Performance4.85%5.13%5.32%2.28%
1 Month Performance9.18%9.67%13.56%16.43%
1 Year Performance17.90%-0.88%17.86%8.15%

Supernus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SUPN
Supernus Pharmaceuticals
2.1049 of 5 stars
$33.07
-0.4%
$36.00
+8.9%
+15.4%$1.85B$668.00M30.94580Positive News
JAZZ
Jazz Pharmaceuticals
4.9501 of 5 stars
$103.58
+5.9%
$182.79
+76.5%
+2.2%$6.38B$4.06B14.593,200
PRGO
Perrigo
4.6749 of 5 stars
$26.99
-0.1%
$33.00
+22.3%
-7.2%$3.68B$4.34B-23.078,900Positive News
PCRX
Pacira BioSciences
2.1942 of 5 stars
$25.09
-0.1%
$26.44
+5.4%
-12.6%$1.16B$700.97M-12.36720Positive News
OMER
Omeros
3.8755 of 5 stars
$3.80
-38.5%
$22.50
+492.1%
-0.3%$221.56MN/A-1.65210Earnings Report
Analyst Upgrade
Analyst Revision
High Trading Volume
NKTR
Nektar Therapeutics
3.9413 of 5 stars
$0.71
+21.4%
$4.50
+529.5%
-60.7%$133.03M$98.43M-0.85220
ASMB
Assembly Biosciences
3.6296 of 5 stars
$12.35
+0.9%
$33.00
+167.2%
-2.6%$94.33M$28.52M-1.98100
CPIX
Cumberland Pharmaceuticals
0.9425 of 5 stars
$5.27
+12.1%
N/A+216.4%$73.61M$37.87M-6.8480
LLY
Eli Lilly and Company
4.9796 of 5 stars
$755.28
+2.8%
$1,002.80
+32.8%
-4.8%$715.80B$49.00B64.5039,000Trending News
High Trading Volume
JNJ
Johnson & Johnson
4.9576 of 5 stars
$153.88
-0.2%
$171.82
+11.7%
+1.5%$370.24B$89.33B23.14152,700Positive News
ABBV
AbbVie
4.8412 of 5 stars
$189.85
+2.8%
$211.41
+11.4%
+12.2%$335.83B$57.37B79.1050,000Trending News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:SUPN) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners